Auranofin: bane or bonanza for the nonrheumatologist.
The availability of an oral gold preparation in the treatment of rheumatoid arthritis, with a claim to being effective yet safer than parenteral gold, will most certainly attract the attention of physicians and patients who previously would not have used chrysotherapy. Cardinal clinical features that may be especially helpful to the nonrheumatologist in the diagnosis of rheumatoid arthritis are outlined. The often unpredictable course of rheumatoid arthritis is stressed, emphasizing the need for an adequate trial of nonsteroidal anti-inflammatory drug therapy before instituting the use of a potentially more toxic remission-inducing drug such as gold. The absence of an immediate flare of synovitis, should the use of oral gold be sporadic, will aggravate the problem of patient noncompliance. Techniques to minimize this problem will be noted. Perseverence and careful record keeping by physicians not necessarily comfortable with the long-term management of chronic disease must be part of the therapeutic program.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006046:Gold / Q000031:analogs & derivatives*; D006801:Humans; D008499:Medical Records; D010347:Patient Care Planning; D010349:Patient Compliance; D010353:Patient Education as Topic; D010820:Physicians
D000893:Anti-Inflammatory Agents; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold